Tute Genomics, a cloud-based platform that can rapidly analyze and annotate personal genomes has raised over $3.9 million in Series A funding from a strategic group of investors, including internationally recognized Intermountain Healthcare, an integrated network of 22 hospitals and 185 physician clinics. Other major investors include Healthbox, a platform for innovation and entrepreneurship in healthcare, and China-based Tencent, one of the largest Internet companies in the world.
Tute Genomics’s cloud-based clinical genome interpretation platform enables researchers and clinicians to utilize human genome data for scientific discovery and individualized treatment. Tute Genomics has assembled a comprehensive genetic database of functional annotations for single nucleotide variants (SNVs) in the human genome. The database contains a proprietary Tute score and Tute prediction – a scoring system to predict whether a SNP or indel is likely to be associated with Mendelian phenotypes. Within a few clicks, researchers are able to generate a Clinical Summary Report viewable as PDF or in the patient portal.
“Tute Genomics has worked tirelessly to make clinical interpretation and reporting of genomic data accessible to healthcare providers, and international investors have taken notice,” stated Kai Wang, PhD, President and Chairman of Tute Genomics.
The genome revolution is here, and Tute envisions a future where genome sequencing is part of routine clinical care, with genomic data integrated into medical records where it is most useful and actionable, giving doctors and patients alike access to genomic information at their fingertips. Genomics is changing healthcare as we know it, and with this new support from strategic investment partners, Tute is well poised to help shape the future of medicine: unlocking the genome, personalizing treatment, and accelerating discovery.
